GleamWall
中文EN

BRTX BioRestorative Therapies, Inc.

Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1505497 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.5%
TTM net income YoY8.6%
TTM EPS YoY27.9%
Revenue 3-yr CAGR38.4%
Net income 3-yr CAGR—

Margins

Gross margin92.1%
Operating margin-3,975.0%
Net margin-3,089.6%
FCF margin—
EBITDA margin-3,916.2%

Returns

ROE-241.1%
ROA-147.7%
ROIC (approx.)-465.4%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets34.8%
Debt / equity0.00x
Current ratio2.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.07x
Accruals ratio10.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-30
Income statement
Revenue$23,170$19,600$11,800$303,300$25,000$43,300$233,600$89,100
Cost of revenue$7,385$1,636$10,570$8,729$2,909$3,339$18,243$6,490
Gross profit$15,785$17,964$1,230$294,571$22,091$39,961$215,357$82,610
R&D expense$1.93M$2.63M$2.59M$2.23M$2.65M$1.70M$1.45M$1.45M
SG&A expense$1.48M$1.22M$1.12M$1.37M$2.18M$1.03M$1.05M$1.10M
Operating income-$3.39M-$3.83M-$3.71M-$3.31M-$4.81M-$2.69M-$2.29M-$2.47M
Net income-$2.15M-$3.21M-$3.04M-$2.66M-$5.34M-$1.64M-$1.09M-$4.03M
EBITDA-$3.33M-$3.77M-$3.66M-$3.25M-$4.76M-$2.64M-$2.24M-$2.42M
EPS (basic)-0.12—-0.33-0.30-0.64—-0.13-0.50
EPS (diluted)-0.12—-0.33-0.30-0.64—-0.13-0.50
Weighted avg. shares (diluted)17.73M—9.12M8.74M8.36M—8.12M8.12M
Banking
Net interest income—$34,586$57,740$73,915$99,966$118,988$158,547$175,945
Balance sheet
Cash & equivalents$3.11M$1.51M$602,444$1.56M$1.23M$547,890$1.49M$2.25M
Short-term investments$479,351$1.44M$3.89M$5.83M$7.88M$10.18M$11.60M$12.43M
Receivables$13,300$15,500$13,400$15,000$25,000$188,400$165,000$27,400
Current assets$3.80M$3.14M$4.71M$7.60M$9.36M$11.14M$13.51M$15.00M
PP&E, net$328,810$358,767$309,498$339,681$369,992$362,936$378,434$345,807
Intangibles$511,761$534,198$556,634$579,071$601,508$623,945$646,381$668,818
Total assets$4.64M$4.08M$5.64M$8.52M$10.33M$12.28M$14.57M$16.12M
Current liabilities$1.61M$3.72M$3.44M$3.67M$4.18M$3.75M$4.58M$5.32M
Total liabilities$1.61M$3.72M$3.44M$3.67M$4.18M$3.75M$4.58M$5.32M
Shareholders' equity$3.03M$356,744$2.21M$4.85M$6.14M$8.53M$9.99M$10.80M
Shares outstanding25.48M8.88M7.98M7.98M7.50M6.92M6.92M6.92M
Cash flow statement
Operating cash flow-$3.81M-$2.42M-$2.90M-$2.69M-$2.78M-$2.35M-$1.70M-$1.87M
Capital expenditure—$79,669$0$0$36,400$12,434$58,459—
Free cash flow—-$2.49M-$2.90M-$2.69M-$2.82M-$2.36M-$1.76M—
Investing cash flow$968,447$2.40M$2.00M$2.13M$2.37M$1.53M$936,753$2.97M
Financing cash flow$4.44M$923,243-$49,308$888,138$1.09M-$126,316$0-$12,843
Depreciation & amortization$52,394$52,836$52,620$52,748$51,781$50,369$48,269$47,705
Stock-based compensation$290,215$447,860$399,932$468,708$2.01M$175,625$284,245$324,322
Share buybacks$0———————

Free plan shows the latest 8 periods; Pro shows all 64 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.